<DOC>
	<DOCNO>NCT02982395</DOCNO>
	<brief_summary>The purpose study determine whether Nanoxel®M effective treatment patient recurrent Ta T1 experience treatment failure least one prior BCG intravesical treatment .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Histologically confirm diagnosis superficial transitional cell carnimoma bladder ( Ta , T1 ) Recurrent superficial bladder cancer refractory Bacillus CalmetteGuerin ( BCG ) No previous intravesical therapy 6 week No history prior radiation pelvis Peripheral neuropathy ≤ grade 1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 t0 2 Adequate hematopoietic hepatic parameter Muscle invasive disease ( T2T4 ) Any malignancy diagnose within 2 year study entry ( Except basal squamous cell skin cancer noninvasive cancer cervix ) Participation research protocol involve administration investigational agent within 3 month study entry History sensitivity reaction docetaxel Prescribed immunosuppressive medication confound medical condition Female patient pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Nanoxel M</keyword>
	<keyword>Docetaxel PM</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>BCG</keyword>
	<keyword>BCG refractory</keyword>
	<keyword>Non muscle invasive bladder cancer</keyword>
	<keyword>intravesical</keyword>
	<keyword>superficial bladder cancer</keyword>
	<keyword>Urothelial carcinoma</keyword>
	<keyword>Transitional cell carcinoma</keyword>
</DOC>